Regular ivermectin use may cut risk of contracting Covid-19, claims study

According to a review of available data by researcher, the medicine can help end the pandemic

A medical doctor and an industrialist volunteer wearing protective masks and a glove tries out a 3D-printed face mask at a workshop in Basra, Iraq 	Photo: REUTERS
Press Trust of India New Delhi
2 min read Last Updated : May 11 2021 | 8:52 AM IST

Regular use of the oral antiparasitic drug ivermectin may significantly reduce the risk of contracting COVID-19, according to a review of available data by researchers who claim the medicine can help end the pandemic.

The research, published in the May-June issue of the American Journal of Therapeutics, is the most comprehensive review of the available data on ivermectin taken from clinical, in vitro, animal, and real-world studies, its authors said.

"We conducted the most comprehensive review of the available data on ivermectin," said Pierre Kory, president and chief medical officer of the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of medical and scientific experts, which led the study.

"We applied the gold standard to qualify the data reviewed before concluding that ivermectin can end this pandemic," Kory said in a statement.

Ivermectin is an oral drug is used as a prescription medication to treat parasitic infections.

A focus of the study was on the 27 controlled trials available in January 2021, 15 of which were randomised controlled trials (RCT's).

The authors found large, statistically significant reduction in mortality, time to recovery and viral clearance in COVID-19 patients treated with ivermectin.

To evaluate the efficacy of ivermectin in preventing COVID-19, three RCT's and five observational controlled trials including almost 2,500 patients were analysed.

All studies reported that ivermectin significantly reduces the risk of contracting COVID-19 when used regularly, the authors said.

Many regions around the world now recognise that ivermectin is a powerful prophylaxis and treatment for COVID-19, the researchers said.

The results as seen in this latest study demonstrate that the ivermectin distribution campaigns repeatedly led to "rapid population-wide decreases in morbidity and mortality," they said.

"Our latest research shows, once again, that when the totality of the evidence is examined, there is no doubt that ivermectin is highly effective as a safe prophylaxis and treatment for COVID-19," said Paul E. Marik, founding member of the FLCCC and Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School in the US.

"We are calling on regional public health authorities and medical professionals around the world to demand that ivermectin be included in their standard of care right away so we can end this pandemic once and for all," Marik added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCorona Remediescorona

First Published: May 11 2021 | 8:46 AM IST

Next Story